Literature DB >> 32619695

Fractures in children and adolescents living with perinatally acquired HIV.

Denise L Jacobson1, Wendy Yu2, Rohan Hazra3, Sean Brummel2, Mitchell E Geffner4, Kunjal Patel5, William Borkowsky6, Jiajia Wang2, Janet S Chen7, Ayesha Mirza8, Linda A DiMeglio9.   

Abstract

BACKGROUND: Across numerous settings, bone mineral density for age and sex is lower in children/adolescents living with perinatally-acquired HIV (PHIV) compared to uninfected peers. We assessed incidences of any fracture/any long bone fracture, and osteoporosis prevalence in PHIV and HIV-exposed uninfected (PHEU) participants in the Pediatric HIV/AIDS Cohort Study (PHACS).
METHODOLOGY: Lifetime history of fracture events from birth up to age 20 years was obtained by chart review and/or interview, including age at fracture, mechanism, and bone(s) fractured. Poisson regression models were fit comparing fracture incidence by HIV status adjusted for age, sex, and race, with effect modification by age (<6, ≥6 yr).
RESULTS: PHIV (N = 412) were older (median 17.5 vs 16.7 yr) and more frequently reported black race (72% vs 61%) than PHEU children/adolescents (N = 206). 17% of PHIV and 12% of PHEU ever reported a fracture. Among children <6 yr, the adjusted incidence rate ratio of ≥1 fracture was higher (7.23; 95% CI 0.98, 53.51) in PHIV than PHEU, but similar among children/adolescents ≥6 years (1.20; 95% CI: 0.77, 1.87). Results were similar for long bone fracture. The most common fracture mechanisms were falling to the ground from a standing height (23.6% PHIV vs 8.8% PHEU) and sports injuries (21.3% vs 32.4%), and the most commonly fractured sites were the forearm and small bones of the wrist/hands. None of the children had osteoporosis.
CONCLUSIONS: Among children/adolescents ≥6 yr of age, fractures were similar by perinatal HIV status. Prospective, targeted collection of fracture history will be necessary to determine rates of fracture as PHIV and PHEU age into adulthood.
SUMMARY: Lifetime fracture history was collected in children/adolescents living with perinatally-acquired HIV (PHIV) and HIV-exposed uninfected (PHEU) children from birth up to age 20 years. Fracture incidence was higher in PHIV compared to PHEU among children <6 years old, but not among older children/adolescents.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Children; Fracture; HIV; Perinatal infection; Tenofovir

Mesh:

Year:  2020        PMID: 32619695      PMCID: PMC7484335          DOI: 10.1016/j.bone.2020.115515

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  42 in total

1.  Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy.

Authors:  George K Siberry; Denise L Jacobson; Heidi J Kalkwarf; Julia W Wu; Linda A DiMeglio; Ram Yogev; Katherine M Knapp; Justin J Wheeler; Laurie Butler; Rohan Hazra; Tracie L Miller; George R Seage; Russell B Van Dyke; Emily Barr; Mariam Davtyan; Lynne M Mofenson; Kenneth C Rich
Journal:  Clin Infect Dis       Date:  2015-06-09       Impact factor: 9.079

2.  Impact of Antiretroviral Drugs on Fracture Risk in HIV-Infected Individuals: A Case-Control Study Nested Within the French Hospital Database on HIV (FHDH-ANRS CO4).

Authors:  Dominique Costagliola; Valérie Potard; Sylvie Lang; Sophie Abgrall; Claudine Duvivier; Hugues Fischer; Véronique Joly; Jean-Marc Lacombe; Marc-Antoine Valantin; Murielle Mary-Krause; Sylvie Rozenberg
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

3.  Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P2C2 human immunodeficiency virus multicenter study.

Authors:  T L Miller; K A Easley; W Zhang; E J Orav; D M Bier; E Luder; A Ting; W T Shearer; J H Vargas; S E Lipshultz
Journal:  Pediatrics       Date:  2001-12       Impact factor: 7.124

4.  Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.

Authors:  Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

5.  Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

Authors:  Aditya H Gaur; Hilda Kizito; Wasana Prasitsueubsai; Natella Rakhmanina; Mohammed Rassool; Rana Chakraborty; Jagmohan Batra; Pope Kosalaraksa; Wicharn Luesomboon; Danielle Porter; Yongwu Shao; Michael Myers; Lillian Ting; Devi SenGupta; Erin Quirk; Martin S Rhee
Journal:  Lancet HIV       Date:  2016-10-17       Impact factor: 12.767

6.  CDC growth charts: United States.

Authors:  R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson
Journal:  Adv Data       Date:  2000-06-08

7.  Bone mineral density in children and adolescents with perinatal HIV infection.

Authors:  Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

Review 8.  Does systemic inflammation and immune activation contribute to fracture risk in HIV?

Authors:  Tara McGinty; Paria Mirmonsef; Patrick W G Mallon; Alan L Landay
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

9.  Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.

Authors:  Denise L Jacobson; Jane C Lindsey; Catherine M Gordon; Jack Moye; Dana S Hardin; Kathleen Mulligan; Grace M Aldrovandi
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

10.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Authors:  Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister
Journal:  Lancet Infect Dis       Date:  2015-11-02       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.